Malachite Innovations, Inc. MLCT
We take great care to ensure that the data presented and summarized in this overview for MALACHITE INNOVATIONS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MLCT
View allLatest Institutional Activity in MLCT
Top Purchases
Top Sells
About MLCT
Malachite Innovations, Inc., together with its subsidiaries, provides health and wellness products in the United States. It offers a portfolio of approximately 100 novel cannabosides, including glycosylated tetrahydrocannabinol, cannabidiol, cannabidivarin, and cannabinol. The company also develops THC-glycoside (VBX-100), an oral prodrug for the treatment of gastrointestinal diseases, including inflammatory bowel disease and irritable bowel syndrome. In addition, it engages in identifying, investing in, and repositioning environmental situations with a focus on technological innovations and eco-friendly solutions. The company was formerly known as Vitality Biopharma, Inc. and changed its name to Malachite Innovations, Inc. in October 2021. Malachite Innovations, Inc. was incorporated in 2007 and is headquartered in Cleveland, Ohio.
Insider Transactions at MLCT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 21
2023
|
Edward F Feighan Director |
BUY
Open market or private purchase
|
Direct |
666,667
+18.15%
|
$0
$0.15 P/Share
|
|
Dec 21
2023
|
Michael R. Cavanaugh Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,000,000
+34.72%
|
$0
$0.15 P/Share
|
|
Dec 14
2023
|
Joseph E. Lo Conti > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
16,225
+0.34%
|
$0
$0.18 P/Share
|
|
Dec 13
2023
|
Joseph E. Lo Conti > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,400
+0.03%
|
$0
$0.18 P/Share
|
|
Dec 12
2023
|
Joseph E. Lo Conti > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
89,158
+0.92%
|
$0
$0.16 P/Share
|
|
Oct 30
2023
|
Joseph E. Lo Conti > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
666,667
+4.72%
|
-
|
|
Aug 24
2023
|
Indemnity National Insurance CO > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
6,666,667
+16.67%
|
$0
$0.15 P/Share
|
|
Apr 28
2023
|
Edward F Feighan Director |
BUY
Open market or private purchase
|
Direct |
30,000
+1.24%
|
$0
$0.2 P/Share
|
|
Apr 26
2023
|
Edward F Feighan Director |
BUY
Open market or private purchase
|
Direct |
2,000
+0.08%
|
$0
$0.2 P/Share
|
|
Apr 25
2023
|
Edward F Feighan Director |
BUY
Open market or private purchase
|
Direct |
2,000
+0.08%
|
$0
$0.2 P/Share
|
|
Apr 21
2023
|
Edward F Feighan Director |
BUY
Open market or private purchase
|
Direct |
15,000
+0.32%
|
$0
$0.2 P/Share
|
|
Apr 19
2023
|
Edward F Feighan Director |
BUY
Open market or private purchase
|
Direct |
1,000
+0.04%
|
$0
$0.18 P/Share
|
|
Apr 11
2023
|
Edward F Feighan Director |
BUY
Open market or private purchase
|
Direct |
333,333
+12.47%
|
$0
$0.15 P/Share
|
|
May 10
2022
|
Joseph E. Lo Conti > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
6,666,667
+34.25%
|
$0
$0.15 P/Share
|
|
Jul 29
2021
|
Joseph E. Lo Conti > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,000
+0.02%
|
$0
$0.2 P/Share
|
|
Jul 20
2021
|
Joseph E. Lo Conti > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
13,000
+0.28%
|
$0
$0.2 P/Share
|
|
Jul 19
2021
|
Joseph E. Lo Conti > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
127,000
+0.9%
|
$0
$0.18 P/Share
|
|
Jul 09
2021
|
Joseph E. Lo Conti > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
20,000
+0.44%
|
$0
$0.19 P/Share
|
|
May 11
2021
|
Joseph E. Lo Conti > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
20,000
+0.22%
|
$0
$0.18 P/Share
|
|
Feb 05
2021
|
Brandon Joel Zipp Chief Science Officer |
BUY
Open market or private purchase
|
Direct |
19,071
+22.96%
|
$0
$0.19 P/Share
|